Intra Cellular Therapies reported $46.98M in Trade Debtors for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Trade Debtors Change
Acadia Pharmaceuticals ACAD:US $ 68.89M 5.41M
ALKERMES ALKS:US 262.33M 7.83M
Biocryst Pharmaceuticals BCRX:US $ 41.49M 5.08M
Biogen BIIB:US $ 2003.5M 17.9M
Bristol Myers Squibb BMY:US $ 12540M 4029M
Cytokinetics CYTK:US $ 1.97M 4.08M
Esperion Therapeutics ESPR:US 27.84M 2.73M
Gilead Sciences GILD:US $ 4118M 331M
Halozyme Therapeutics HALO:US $ 189.37M 75.61M
Intra Cellular Therapies ITCI:US $ 46.98M 14.14M
JAZZ PHA JAZZ:US $ 594.03M 21.64M
Marinus Pharmaceuticals MRNS:US 3M 511K
Nektar Therapeutics NKTR:US $ 10.01M 20.21M
Neurocrine Biosciences NBIX:US $ 279M 15.5M
Novartis NVS:US $ 8910M 232M
Redhill Biopharma RDHL:US $ 25.93M 5.74M
Supernus Pharmaceuticals SUPN:US $ 158.06M 12.91M
United Therapeutics UTHR:US $ 173.4M 2.9M
Vanda Pharmaceuticals VNDA:US $ 28.8M 1.69M